The US Food and Drug Administration (FDA) has approved a product known as enzalutamide (Xtandi®) to be used in a new way. The body, after an in-depth review says that it is ideal for handling a condition called prostate cancer (mHSPC). A close outlook Sometime back, the company gave its approval to the product for […]
Michael Jung
Recent Posts
Summary of Concussion
OMID Posts 2022 Annual Report and Provides Update
AmpliTech Records a New Benchmark at Satellite 2023 Show in Washington, D.C.
Premier Biomedical Inc. (OTC: BIEI), Welcomes Officers, Directors and Key Advisors
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
Popular Post
-
Sports Gambling and the Horse Racing Market
-
ZICIX+CTIP-FII RECEIVES NOTICE TO PROCEED FROM PROJECT OWNER TO START THE $20 MILLION SENIOR CITIZENS RESIDENCE PROJECT IN NEWARK, NEW JERSEY
-
Mass Megawatts Targets Solar Customers throughout the Northeast and its Solar Tracker’s Time of Use (TOU) Rates Advantages Become More Important When California’s NEM 3 Takes Effect Next Month
-
Principal Solar to Acquire Minerva-Rockdale Leases, Wells, and Assets
-
Kona Gold Beverage, Inc Announces its Ooh La Lemin Lemonades to be sold in Town Pump Convenience Stores in Montana
